Format

Send to

Choose Destination
Mycopathologia. 2010 Nov;170(5):291-313. doi: 10.1007/s11046-010-9324-3. Epub 2010 Jun 5.

Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Author information

1
Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, 1 Shields Avenue, Tupper Hall, Davis, CA 95616, USA. george.thompson@ucdmc.ucdavis.edu

Abstract

Isavuconazole is a new triazole currently undergoing phase III clinical trials. This compound has shown in vitro activity against a large number of clinically important yeasts and moulds including Aspergillus spp., Fusarium spp., Scedosporium spp., Candida spp., the Zygomycetes and Cryptococcus spp. Similar to voriconazole, reduced in vitro activity is seen against Histoplasma capsulatum. In vivo efficacy has been demonstrated in murine models of invasive aspergillosis and candidiasis. Additionally, there are several potential pharmacokinetic and drug-drug interaction advantages of this compound over existing antifungal agents. This review summarizes existing data that has been either published or presented at international symposia.

PMID:
20524153
DOI:
10.1007/s11046-010-9324-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center